醫療事務的評價(美國)- 多發性硬化症

根據這項對100名美國神經科醫生的最新調查，幾大多發性硬化症藥物品牌的醫療事務團隊在幾個關鍵領域的表現仍有待提升。

本報告探討了美國醫療事務部門及其如何滿足多發性硬化症醫生的高期望。報告也比較了各公司領先的多發性硬化症藥物品牌的醫療事務團隊的當前表現。

關鍵問題解答

• 1. 醫師與醫療事務團隊的互動頻率如何？這種互動頻率是增加了還是減少了？
• 2. 醫師目前如何使用醫療事務團隊提供的服務？
• 3. 醫療事務支援的哪些面向對醫師最重要？他們對所提供的支援有多滿意？
• 4. 醫師希望醫療事務團隊與醫療事務團隊之間進行哪種類型的互動？他們希望這種互動的頻率是多少？
• 5. 醫療事務團隊在多大程度上滿足了醫師的需求？
• 6. 醫療事務團隊在特定品牌的表現是低於還是高於預期？
• 7. 未來如何改善醫療事務服務，以便更好地滿足醫師的需求？
• 8. 競爭對手的醫療事務團隊在哪些方面最弱，哪些方面最強？

According to this latest survey of 100 US neurologists, the performance of multiple sclerosis medical affairs teams for some high profile brands still has a way to go in some key areas. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied. This report reveals how medical affairs can better meet the high expectations of physicians treating multiple sclerosis. It compares the current performance of medical affairs teams for leading treatments for multiple sclerosis from various companies.

Key Questions Answered:

• 1. How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
• 2. In what ways do physicians currently use the services provided by Medical Affairs teams
• 3. What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
• 4. What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
• 5. How successful are Medical Affairs teams at meeting physician needs?
• 6. Are Medical Affairs teams falling short or exceeding goals with any particular brands?
• 7. How can Medical Affairs services be improved to better meet the needs of physicians in the future?
• 8. In what areas are your competitors' Medical Affairs teams weakest and strongest?

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.